Skip to main content
Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
1.941
+0.021 (1.09%)
At close: Nov 13, 2026, 4:00 PM EST
1.920
-0.021 (-1.08%)
After-hours: Nov 13, 2026, 7:30 PM EST

Propanc Biopharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Selling, General & Admin
16.6515.2833.761.291.531.73
Research & Development
1.020.630.220.250.250.26
Other Operating Expenses
4.412.2823.3---
Operating Expenses
22.0818.1957.281.541.781.99
Operating Income
-22.08-18.19-57.28-1.54-1.78-1.99
Interest Expense
-0.14-0.43-0.56-0.67-0.53-0.57
Interest & Investment Income
000000.01
Currency Exchange Gain (Loss)
0.090.03-0.090.020.01-0.04
Other Non Operating Income (Expenses)
-0.09-0.09-0.120.18-0.53-0.1
EBT Excluding Unusual Items
-22.23-18.68-58.05-2-2.83-2.7
Legal Settlements
-0.15-0.15----
Other Unusual Items
-0.23-0.04-0.870.050.04-0.02
Pretax Income
-22.61-18.86-58.92-1.95-2.79-2.71
Income Tax Expense
----0.13-0.13-0.05
Net Income
-22.61-18.86-58.92-1.82-2.66-2.66
Preferred Dividends & Other Adjustments
0.930.93-0.190.470.7
Net Income to Common
-23.55-19.79-58.92-2.01-3.13-3.36
Net Income Growth
------
Shares Outstanding (Basic)
000---
Shares Outstanding (Diluted)
000---
Shares Change
878.12%607.94%----
EPS (Basic)
-85.38-176.16-3712.17---
EPS (Diluted)
-85.38-176.16-3712.17---
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
-5.72-5.69-0.41-0.94-1.11-1.44
Free Cash Flow Per Share
-20.73-50.61-25.53---
EBITDA
-22.08-18.18-57.28-1.54-1.77-1.99
D&A For EBITDA
000000
EBIT
-22.08-18.19-57.28-1.54-1.78-1.99